10 results on '"Khachatryan, Naira"'
Search Results
2. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study
- Author
-
Korotych, Oleksandr, Achar, Jay, Gurbanova, Elmira, Hovhannesyan, Arax, Lomtadze, Nino, Ciobanu, Ana, Skrahina, Alena, Dravniece, Gunta, Kuksa, Liga, Rich, Michael, Khachatryan, Naira, Germanovych, Myroslava, Kadyrov, Abdullat, Terleieva, Iana, Akhundova, Irada, Adenov, Malik, Durdyeva, Myahri, Kiria, Nana, Parpieva, Nargiza, Yatskevich, Natalia, Jumayev, Rovshen, Nurov, Rustam, Diktanas, Saulius, Vilc, Valentina, Migliori, Giovanni Battista, and Yedilbayev, Askar
- Published
- 2024
- Full Text
- View/download PDF
3. A multi-cohort genome-wide association study in African ancestry individuals reveals risk loci for primary open-angle glaucoma
- Author
-
Verma, Shefali S., Gudiseva, Harini V., Chavali, Venkata R.M., Salowe, Rebecca J., Bradford, Yuki, Guare, Lindsay, Lucas, Anastasia, Collins, David W., Vrathasha, Vrathasha, Nair, Rohini M., Rathi, Sonika, Zhao, Bingxin, He, Jie, Lee, Roy, Zenebe-Gete, Selam, Bowman, Anita S., McHugh, Caitlin P., Zody, Michael C., Pistilli, Maxwell, Khachatryan, Naira, Daniel, Ebenezer, Murphy, Windell, Henderer, Jeffrey, Kinzy, Tyler G., Iyengar, Sudha K., Peachey, Neal S., Taylor, Kent D., Guo, Xiuqing, Chen, Yii-Der Ida, Zangwill, Linda, Girkin, Christopher, Ayyagari, Radha, Liebmann, Jeffrey, Chuka-Okosa, Chimd M., Williams, Susan E., Akafo, Stephen, Budenz, Donald L., Olawoye, Olusola O., Ramsay, Michele, Ashaye, Adeyinka, Akpa, Onoja M., Aung, Tin, Wiggs, Janey L., Ross, Ahmara G., Cui, Qi N., Addis, Victoria, Lehman, Amanda, Miller-Ellis, Eydie, Sankar, Prithvi S., Williams, Scott M., Ying, Gui-shuang, Cooke Bailey, Jessica, Rotter, Jerome I., Weinreb, Robert, Khor, Chiea Chuen, Hauser, Michael A., Ritchie, Marylyn D., and O’Brien, Joan M.
- Published
- 2024
- Full Text
- View/download PDF
4. Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality
- Author
-
Kempen, John H., Newcomb, Craig W., Washington, Terri L., Foster, C. Stephen, Sobrin, Lucia, Thorne, Jennifer E., Jabs, Douglas A., Suhler, Eric B., Rosenbaum, James T., Sen, H. Nida, Levy-Clarke, Grace A., Nussenblatt, Robert B., Bhatt, Nirali P., Lowder, Careen Y., Goldstein, Debra A., Leiderman, Yannek I., Acharya, Nisha R., Holland, Gary N., Read, Russell W., Dunn, James P., Dreger, Kurt A., Artornsombudh, Pichaporn, Begum, Hosne A., Fitzgerald, Tonetta D., Kothari, Srishti, Payal, Abhishek R., Daniel, Ebenezer, Gangaputra, Sapna S., Kaçmaz, R. Oktay, Liesegang, Teresa L., Pujari, Siddharth S., Khachatryan, Naira, Maghsoudlou, Armin, Suga, Hilkiah K., Pak, Clara M., Helzlsouer, Kathy J., and Buchanich, Jeanine M.
- Published
- 2023
- Full Text
- View/download PDF
5. Availability and costs of medicines for the treatment of tuberculosis in Europe
- Author
-
Hasan Hafizi, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, and van Leth, Frank
- Published
- 2023
- Full Text
- View/download PDF
6. The safety of modified, all-oral shorter tuberculosis regimens in Armenia.
- Author
-
Atshemyan, Hakob, Khachatryan, Naira, Khachatryan, Anush, and Mirzoyan, Narine
- Subjects
- *
DRUG therapy for tuberculosis , *PERIPHERAL neuropathy , *ANEMIA , *COMBINATION drug therapy , *PATIENT safety , *DRUG side effects , *RESEARCH funding , *TREATMENT duration , *TREATMENT effectiveness , *DRUG efficacy , *JOINT pain , *RIFAMPIN , *DRUG resistance , *PATIENT aftercare , *EVALUATION , *DISEASE risk factors - Abstract
BACKGROUND: The implementation of modified, all-oral shorter regimens for treatment of rifampicin-resistant tuberculosis has started in Armenia since August 2020 under the conditions of operational research. OBJECTIVE: This study aims to evaluate the safety and effectiveness of shorter regimens. METHODS: We evaluated cumulative incidence rates of serious adverse events, adverse events of grade 3 and greater and events resulting in treatment modifications or suspension for 52 study participants. RESULTS: A new, different pattern of adverse events emerged compared with the previous evaluations of drug safety of treatment for rifampicin-resistant tuberculosis. Arthralgia (23.1%) and peripheral neuropathy (21.2%) took leading positions among the adverse events resulting in modifications of treatment. Some adverse events of interest (prolonged QT interval, elevated liver enzymes and anemia) remained relevant for the patients receiving new combinations of anti-TB drugs. The other adverse events (impaired hearing, acute kidney injury and hypokalemia) lost their significance for safety surveillance of rifampicin-resistant tuberculosis treatment. One unexpected serious adverse event (lymphoproliferative skin lesion) brought to a "failed treatment" outcome. The other serious adverse event was anemia. CONCLUSION: The shorter regimens proved to be safe and effective for treatment of rifampicin-resistant tuberculosis, but proper follow-up of adverse events is necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Cataract Blindness in Armenia: The Results of Nationwide Rapid Assessment of Avoidable Blindness (RAAB).
- Author
-
Giloyan, Aida, Khachatryan, Naira, Paduca, Ala, Limburg, Hans, and Petrosyan, Varduhi
- Subjects
- *
CATARACT , *BLINDNESS , *CATARACT surgery , *POPULATION aging - Abstract
This study assessed the prevalence of cataract blindness, cataract surgical coverage (CSC), effective CSC, visual outcome after cataract surgery, and barriers to cataract surgery in a population aged 50 years and older in Armenia using Rapid Assessment of Avoidable Blindness (RAAB) methodology. The study sample included 2258 individuals aged 50 years and older who were randomly selected from 11 provinces of Armenia in 2019 following the RAAB methodology. The study team randomly selected 50 clusters, 50 people in each. The RAAB survey form was used to collect information on cataract blindness, visual outcome after cataract surgery, and barriers to cataract surgery. The mean age of the participants was 65.3 (SD = 9.9) ranging from 50 to 99. The majority of participants were women (65.6%). Age- and sex-adjusted prevalence of blindness due to all causes was 1.5%; of which 36.4% was bilaterally blind due to cataract. The CSC and effective CSC at a cataract surgical threshold of <6/12 were 55.1% and 24.4%, respectively. Good outcome was reported in 43.7% of eyes after cataract surgery, borderline in 37.2% of eyes, and poor outcome in 19.1%. The main barriers to cataract surgery included "cost," "need not felt," or "fear." The prevalence of cataract blindness in our study was higher compared to high-income regions and lower than estimates from South/Southeast Asia. This study suggests the urgent need to update the National Strategic Plan to prevent blindness in Armenia with a focus on improving the quality and coverage of cataract surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Nationwide Rapid Assessment of Avoidable Blindness (RAAB) in Armenia.
- Author
-
Khachatryan, Naira, Giloyan, Aida, Paduca, Ala, Limburg, Hans, and Petrosyan, Varduhi
- Subjects
- *
BLINDNESS , *VISION disorders , *REFRACTIVE errors , *VISUAL acuity , *EYE care , *LOW vision - Abstract
This study aimed to estimate the prevalence and main causes of blindness and visual impairment in population aged 50 years and older in Armenia using Rapid Assessment of Avoidable Blindness (RAAB) methodology. The study team randomly selected 50 clusters (each consisting of 50 people) from all 11 regions of Armenia. Data on participants' demographics, presenting visual acuity, pinhole visual acuity, principal cause of presenting visual acuity, spectacle coverage, uncorrected refractive error (URE), and presbyopia were collected using the RAAB survey form. Four teams of trained eye care professionals completed data collection in 2019. Overall, 2,258 people of 50 years and older participated in the study. The age- and gender- adjusted prevalence of bilateral blindness, severe and moderate visual impairment were 1.5% (95% CI: 1.0–2.1), 1.6% (95% CI: 1.0–2.2) and 6.6% (95% CI: 5.5–7.7), respectively. The main causes of blindness were cataract (43.9%) and glaucoma (17.1%). About 54.6% and 35.3% of participants had URE and uncorrected presbyopia, respectively. The prevalence of bilateral blindness and functional low vision increased with age and was the highest in participants 80 years and older. The rate of bilateral blindness was comparable with findings from countries that share similar background and confirmed that untreated cataract was the main cause of blindness. Given that cataract blindness is avoidable, strategies should be developed aiming to further increase the volume and quality of cataract care in Armenia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Availability and costs of medicines for the treatment of tuberculosis in Europe
- Author
-
Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, van Leth, Frank, Hafizi, Hasan, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Andersen, Åse Bengård, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Health Economics and Health Technology Assessment, APH - Global Health, APH - Methodology, and Microbes in Health and Disease (MHD)
- Subjects
Microbiology (medical) ,Evropa ,Extensively Drug-Resistant Tuberculosis ,Antitubercular Agents ,Capacity building ,610 Medicine & health ,MDR-TB ,Mycobacterium tuberculosis - terapija z zdravili ,Microbial Sensitivity Tests ,Antimicrobial resistance ,Medicines ,Mycobacterium tuberculosis - drug therapy ,SDG 3 - Good Health and Well-being ,Tuberculosis, Multidrug-Resistant ,Humans ,Tuberculosis ,tuberkuloza - terapija z zdravili ,health care costs - drug therapy ,Mycobacterium tuberculosis ,General Medicine ,END-TB strategy ,udc:616-002 ,tuberculosis - drug therapy ,Costs ,stroški zdravstvene oskrbe - terapija z zdravili ,Europe ,Infectious Diseases ,Availability of medicines - Abstract
Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries.Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries.Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were €44 (minimum–maximum, €15–152), €764 (minimum–maximum, €542–15152), and €8709 (minimum–maximum, €7965–11759) in middle-income countries (n = 12) and €280 (minimum–maximum, €78–1084), €29765 (minimum–maximum, €11116–40584), and €217591 (minimum–maximum, €82827–320146) in high-income countries (n = 29), respectively.Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis.
- Published
- 2023
10. Corneal Endothelial Transplantation in Uveitis: Incidence and Risk Factors.
- Author
-
Roldan AM, Zebardast N, Pistilli M, Khachatryan N, Payal A, Begum H, Artornsombudh P, Pujari SS, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Bhatt NP, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Buchanich JM, and Kempen JH
- Subjects
- Adult, Cohort Studies, Humans, Incidence, Inflammation complications, Keratoplasty, Penetrating, Middle Aged, Retrospective Studies, Risk Factors, Cataract complications, Corneal Dystrophies, Hereditary complications, Descemet Stripping Endothelial Keratoplasty, Uveitis complications, Uveitis epidemiology, Uveitis surgery
- Abstract
Purpose: To estimate the incidence of corneal endothelial transplantation (CET) and identify risk factors among patients with noninfectious ocular inflammation., Design: Retrospective cohort study., Methods: Adult patients attending United States tertiary uveitis care facilities diagnosed with noninfectious ocular inflammation were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Time-to-event analysis was used to estimate the incidence of CET, including penetrating keratoplasty, Descemet stripping endothelial keratoplasty, or Descemet membrane endothelial keratoplasty procedures. The incidence of CET was calculated. Potential risk factors for CET were also evaluated using Cox regression, accounting for correlation between eyes of the same patient., Results: Overall, 14,264 eyes met eligibility criteria for this analysis, with a median follow-up of 1.8 eye-years. The Kaplan-Meier estimated incidence of CET within 10 years was 1.10% (95% CI, 0.68%-1.53%). Risk factors for CET included age >60 years vs <40 years (adjusted hazard ratio [aHR], 16.5; 95% CI, 4.70-57.9), anterior uveitis and scleritis vs other types (aHR, 2.97; 95% CI, 1.46-6.05; and aHR, 4.14; 95% CI,1.28-13.4, respectively), topical corticosteroid treatment (aHR, 2.84; 95% CI, 1.32-6.13), cataract surgery (aHR, 4.44; 95% CI, 1.73-11.4), tube shunt surgery (aHR, 11.9; 95% CI, 5.30-26.8), band keratopathy (aHR, 5.12; 95% CI, 2.34-11.2), and hypotony (aHR, 7.38; 95% CI, 3.14-17.4). Duration of uveitis, trabeculectomy, peripheral anterior synechia, and ocular hypertension had no significant association after multivariate adjustment., Conclusions: In patients with ocular inflammation, CET occurred infrequently. Tube shunt surgery, hypotony, band keratopathy, cataract surgery, and anterior segment inflammation were associated with increased risk of undergoing CET; these factors likely are associated with endothelial cell damage., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.